Emergent BioSolutions Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Emergent BioSolutions Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.1 times its market value (net debt). Lower than 95% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $52 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $38 tied up three years earlier. More money tied up than 93% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.3×Over the last 3 years its own operating cash paid for 26% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Higher than 65% of Healthcare companies in United States.
Cash Locked Ratio
$52For every $100 of sales, $52 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $38 tied up three years earlier.
More money tied up than 93% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 34%
Sales fell 34% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-34% / -58%In 3 years sales changed by -34% while total assets changed by -58%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
1.1× debtDebt, after subtracting cash, is 1.1 times its market value (net debt).
Lower than 95% of Healthcare companies in United States.
Tangible Assets Ratio
67%Of every $100 the company owns, $67 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 64% of Healthcare companies in United States.
Tangible Net Worth Ratio
16%Of every $100 of net worth, $16 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 66% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Emergent BioSolutions Inc. made a loss over the last year. Emergent BioSolutions Inc. owes $0.69 for every $1 it owns. Emergent BioSolutions Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossEmergent BioSolutions Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.94The share price is 0.94 times Emergent BioSolutions Inc.'s book value per share, lower than 80% of Healthcare companies in United States.
Market cap
$319 MThe total market value of all of Emergent BioSolutions Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$341 MWhat Emergent BioSolutions Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.66Net worth divided by the number of shares. The share price of $6.23 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-40.3%Emergent BioSolutions Inc. lost 40.3% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
Owes vs Owns
0.69×Emergent BioSolutions Inc. owes $0.69 for every $1 it owns (moderate), higher than 72% of Healthcare companies in United States.
Dividend yield
NoneEmergent BioSolutions Inc. does not currently pay a dividend.
Revenue growth
-30%Revenue fell 30% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Profit growth
Back to profitEmergent BioSolutions Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
7.5%Emergent BioSolutions Inc. keeps $7 of every $100 of revenue as net profit.
Cash quality
3.2×Cash from Emergent BioSolutions Inc.'s business was 3.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
1.9×Emergent BioSolutions Inc.'s operating profit covered its interest costs 1.9 times in the year to Dec 2025.
Cash vs debt
Net debtEmergent BioSolutions Inc. had $367 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Emergent BioSolutions Inc.: $319 M ÷ $341 M (30 Jun 2026) = 0.9.
What is Emergent BioSolutions Inc.'s return on equity?
Emergent BioSolutions Inc. lost 40.3% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
How much does Emergent BioSolutions Inc. owe compared with what it owns?
Emergent BioSolutions Inc. owes $0.69 for every $1 it owns (moderate), higher than 72% of Healthcare companies in United States.
Does Emergent BioSolutions Inc. pay a dividend?
No. Emergent BioSolutions Inc. does not currently pay a dividend.
Is Emergent BioSolutions Inc.'s revenue growing?
Revenue fell 30% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.